Hematology

Latest News

Tablet with blue screen and multiple myeloma written in white with a stethoscope on top | Image credit: ibreakstock-stock.adobe.com
CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM

September 14th 2024

Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, teclistamab, in multiple myeloma (MM).

Celiac disease and the body | Image Credit: reineg-stock.adobe.com
Celiac Disease Associated With Varying Risks for Cancers

September 13th 2024

Patients with SCD have reportedly felt stigmatized due to their race, pain, and more | image credit: Andrey Popov - stock.adobe.com
Study: Patients With SCD Report Discrimination Based on Race, Pain, and Other Factors

September 11th 2024

Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com
Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma 

September 5th 2024

red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

September 4th 2024

More News

As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues
December 10th 2013

As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues

Treating lymphoma today starts with an understanding of what is being treated, and the revolution in genetic profiling lets clinicians do that with more precision than ever.
Treating the Signs of Multiple Myeloma Before it Starts
December 8th 2013

Treating the Signs of Multiple Myeloma Before it Starts

Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission especially if stem cell transplantation is a possibility against the toxicity of the treatment itself.
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever
December 8th 2013

Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever

With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.
Site Logo
October 23rd 2013

Challenges in Oncology Practice

AJMC Staff
Site Logo
August 2nd 2013

ASH Releases Analysis on Impact of Medicare Proposed Rules on Hematologists

On July 8, 2012, the Centers for Medicare & Medicaid Services (CMS) released two major Medicare proposed rules impacting payment for physician and hospital outpatient services in 2014. ASH will submit comments to CMS on the proposed rules by the September 6 deadline and would like to incorporate feedback from the Society's practice-based members.
PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD
December 11th 2012

PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD

Henri Stanton
At the 54th Annual Meeting of the American Society of Hematology, John Radford, MD, reported the results of the United Kingdom RAPID trial, in which PET-directed therapy provided an opportunity to avoid involved field radiotherapy, the current standard of care following abbreviated chemotherapy in early stage Hodgkin's lymphoma.
Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD
December 10th 2012

Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD

Bonnie Gillis
Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem cell transplantation reduced the cumulative incidence of graft-versus-host disease in a phase I/II trial reported at the 54th Annual Meeting of the American Society of Hematology.
Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma
December 9th 2012

Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma

Bonnie Gillis
An investigational, weekly, oral proteosome inhibitor called MLN9708 achieved excellent response rates when combined with lenalidomide and dexamethasone as up-front treatment of newly diagnosed patients with multiple myeloma, according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology.
Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL
December 9th 2012

Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL

Bonnie Gillis
Ibrutinib, an investigational Bruton's tyrosine kinase inhibitor, achieved excellent results in clinical trials of patients with chronic lymphocytic leukemia (CLL) presented at the 54th Annual Meeting of the American Society of Hematology.
Extending Anticoagulation With Apixaban Reduces Recurrent VTE
December 9th 2012

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

Henri Stanton
Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.
<1
...
181920212223>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo